|N-(2-二异丙基氨基)乙基)-2-(2-羟基-4,5-二甲氧基苯甲酰胺)噻唑-4-甲酰胺盐酸盐|CsnPharm

CAS No.: 185104-11-4

Acotiamide HCl Catalog No. CSN23387

Synonyms: Z-338;YM443

Acotiamide HCl is the 2HCl form of acotiamide which is an inhibitor of AChE. It also acts as a prokinetic drug through acetylcholinesterase inhibition and muscarinic receptor antagonism that is used for the treatment of functional dyspepsia.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述Acotiamide HCl, an oral first-in-class prokinetic drug. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity^[1]. Acotiamide enhances the effect of acetylcholine in the enteric nervous system, enhances gastric contractility, and accelerates delayed gastric emptying. Acotiamide prolongs gastric accommodation and improves stress-induced impaired gastric accommodation^[2]. Adding acotiamide to gastric acid inhibitors can improve symptoms in patients with refractory NERD (non-erosive reflux disease) ^[3]. Acotiamide is associated with lower antral pressures after nutrient intake, whereas it has no effect on fundic pressures, GE (gastric emptying) rate and symptom perceptions in HVs^[4].
参考文献

[1] Nowlan ML, Scott LJ. Acotiamide: first global approval [published correction appears in Drugs. 2014 Jun;74(9):1059. Nolan, Mary L [corrected to Nowlan, Mary L]]. Drugs. 2013;73(12):1377-1383
[2] Ikeo K, Oshima T, Sei H, et al. Acotiamide improves stress-induced impaired gastric accommodation. Neurogastroenterol Motil. 2017;29(4):10.1111/nmo.12991
[3] Mikami H, Ishimura N, Okada M, et al. Acotiamide Has No Effects on Esophageal Motor Activity or Esophagogastric Junction Compliance. J Neurogastroenterol Motil. 2018;24(2):241-247
[4] Masuy I, Tack J, Verbeke K, Carbone F. Acotiamide affects antral motility, but has no effect on fundic motility, gastric emptying or symptom perception in healthy participants. Neurogastroenterol Motil. 2019;31(4):e13540

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.0533 mL
- 10.2667 mL
- 20.5333 mL
- 5 mM
- 0.4107 mL
- 2.0533 mL
- 4.1067 mL
- 10 mM
- 0.2053 mL
- 1.0267 mL
- 2.0533 mL

技术信息

CAS号	185104-11-4	储存条件	粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C21H31ClN4O5S	运输	蓝冰
分子量	487.01	别名	Z-338;YM443

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

Acotiamide HCl Catalog No. CSN23387

靶点选择性

请登录您的专属账户

确认信息